Important matters:

ESR (01821) subsidiary interests to sell ARA's private equity business are expected to achieve revenue of about 50 million US dollars

Cully Pharmaceutical-B (01672) announced that it will present the final results of the FASN inhibitor ASC40 to treat acne phase II at the 2024 American Academy of Dermatology (AAD) Annual Meeting

Lepu Bio-B (02157): MRG004A for the treatment of pancreatic cancer was granted fast-track status by the FDA

Laikai Pharmaceutical-B (02105) has submitted a clinical trial application for LAE102 new obesity drugs to the US Food and Drug Administration

The main product A400 (EP0031) of Collumbotai Bio-B (06990) was granted Fast Track Qualification by the US Food and Drug Administration

China Biopharmaceutical (01177): “Anlotinib hydrochloride capsules” and “TQB2916 (CD40 agonist)” will announce 5 research results at AACR in 2024

CIMC Motors (01839) plans to repurchase all issued H shares at a premium of about 4.9% to resume trading on March 12

Operating performance:

China Life Insurance (02628)'s cumulative original insurance premium income for the first two months was about 252.7 billion yuan, up 2.8% year on year

Yuyuan Group (00551)'s net consolidated operating income in February was US$606 million, up 0.4% year-on-year

Kingsley Biotechnology (01548): Legendary Biotech's total revenue of US$285 million in 2023 increased 143.7% year-on-year

Pharmacist Gang (09885) released annual results, with revenue of about 16.972 billion yuan, an increase of 18.9% over the previous year

Zhenjiu Li Du (06979) Fa Yingxi expects net profit to increase sharply to no less than 2.3 billion yuan in 2023

SF Express Tongcheng (09699) expects net profit from continuing operations to be no less than 60 million yuan in 2023